BioSpace News Archive

As the biopharma industry responds to the COVID-19 pandemic, some of the area’s companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here’s a look.

Like many biopharma companies, Amgen is evaluating how the COVID-19 pandemic is affecting its operations, supply chain and clinical trial programs.

The following is a roundup of some of this week’s non-coronavirus biopharma news.

4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company developing drug-controlled gene therapies to address intractable diseases of the nervous system.

evitria AG, a global antibody expression service provider, announces that it has crossed the 100-citation threshold on Google Scholars.

Secarna’s approach efficiently targets IDO1 and TDO2, key enzymes that degrade the essential amino acid tryptophan into immunosuppressive kynurenine

Anavex Life Sciences Corp. provided an update on the evolving COVID-19 condition and the Company’s response to its clinical program development.

Senhwa Biosciences, Inc. (TPEx: 6492) announced today that its drug Silmitasertib (CX-4945) was determined to be a potential treatment for COVID -19. To date, COVID -19, has infected over 700,000 people and killed over 34,000 people worldwide. COVID -19 is a novel coronavirus SARS-CoV-2 respiratory disease with currently no proven tre

Study Arm Evaluating 40 MG BID of Rifaximin SSD IR In Combination with Standard of Care Therapy Met Primary Endpoint

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to